Education
About Us
Working with TipRanks
Follow Us
Neurotech International Ltd. (AU:NTI)
ASX:NTI
RESEARCH TOOLSreports
NTI Stock Chart & Stats
Day’s Range― - ―
52-Week RangeAU$0.03 - AU$0.12
Previous CloseN/A
Volume11.09K
Average Volume (3M)952.48K
Market Cap
AU$32.31M
Enterprise ValueAU$52.64M
Total Cash (Recent Filing)AU$446.11K
Total Debt (Recent Filing)AU$34.58K
Price to Earnings (P/E)―
Beta1.44
Next Earnings
Aug 27, 2025EPS Estimate
>-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares Outstanding1,042,122,000
10 Day Avg. Volume1,477,381
30 Day Avg. Volume952,477
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)928.85
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
---
Neurotech International Ltd. News
PremiumCompany Announcements
Neurotech’s NTI164 Receives EU Orphan Drug Designation for Rett Syndrome
PremiumCompany Announcements
Neurotech Retracts Market Opportunity Statement
PremiumCompany Announcements
Neurotech Publishes Positive Phase I/II ASD Trial ResultsPremiumCompany Announcements
Neurotech International to Present at NWR Virtual Healthcare Conference
PremiumCompany Announcements
Neurotech Secures EMA Positive Opinion for NTI164 in Rett Syndrome---
Options Prices
Currently, No data available
---
Ownership Overview
0.18% Insiders
―
Mutual Funds
― Other Institutional Investors
99.82% Public Companies and
Individual Investors
NTI FAQ
What was Neurotech International Ltd.’s price range in the past 12 months?
Neurotech International Ltd. lowest share price was AU$0.03 and its highest was AU$0.12 in the past 12 months.
What is Neurotech International Ltd.’s market cap?
Neurotech International Ltd.’s market cap is AU$32.31M.
When is Neurotech International Ltd.’s upcoming earnings report date?
Neurotech International Ltd.’s upcoming earnings report date is Aug 27, 2025 which is in 149 days.
How were Neurotech International Ltd.’s earnings last quarter?
Neurotech International Ltd. released its earnings results on Feb 27, 2025. The company reported -AU$0.73 earnings per share for the quarter, missing the consensus estimate of -AU$0.005 by -AU$0.725.
Is Neurotech International Ltd. overvalued?
According to Wall Street analysts Neurotech International Ltd.’s price is currently Overvalued.
Does Neurotech International Ltd. pay dividends?
Neurotech International Ltd. does not currently pay dividends.
What is Neurotech International Ltd.’s EPS estimate?
Neurotech International Ltd.’s EPS estimate is >-0.01.
How many shares outstanding does Neurotech International Ltd. have?
Neurotech International Ltd. has 1,042,122,000 shares outstanding.
What happened to Neurotech International Ltd.’s price movement after its last earnings report?
Neurotech International Ltd. reported an EPS of -AU$0.73 in its last earnings report, missing expectations of -AU$0.005. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Neurotech International Ltd.?
Currently, no hedge funds are holding shares in AU:NTI
---
Neurotech International Ltd. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:NTI Sentiment 76%
Sector Average 69%
Sector Average 69%
Insider Transactions
Bought Shares
Worth AU$13.3K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-71.81%
12-Months-Change
Fundamentals
Return on Equity
-223.80%
Trailing 12-Months
Asset Growth
26.87%
Trailing 12-Months
Company Description
Neurotech International Ltd.
Neurotech International Limited, together with its subsidiaries, engages in the research, design, development, and manufacture of medical devices and solutions in Australia. The company is focused on development and commercializing Mente platform, a platform technology to monitor and play role in home-based therapies. Its product includes Mente Autism for the diagnosis and treatment of autism. It also engages in executing of medical research projects; and developing of technological devices. The company was incorporated in 2016 and is based in Nedlands, Australia.
---
Technical Analysis
Cann Group Ltd.
―
Invex Therapeutics Ltd.
―
Althea Group Holdings Ltd.
―
Botanix Pharmaceuticals Limited
―
---